📊 PGEN Key Takeaways
Is Precigen, Inc.. (PGEN) a Good Investment?
Precigen is a severely distressed biotech company with a monthly cash burn rate of ~$7.3M against only $30.2M in cash reserves, yielding a 4-month runway. Despite 146.7% revenue growth, the company loses $25.88 for every dollar of revenue, making profitability unachievable at current scale. The 4.46x debt-to-equity ratio with negative interest coverage creates acute solvency risk.
Why Buy Precigen, Inc.. Stock? PGEN Key Strengths
- Revenue growth of 146.7% YoY demonstrates market traction from near-zero baseline
- Short-term liquidity ratios (3.09x current, 3.08x quick) provide immediate payment capacity
- Net losses improving 41.7% YoY, suggesting loss magnitude may be moderating
PGEN Stock Risks: Precigen, Inc.. Investment Risks
- Critical cash runway of only 4 months at current -$87.8M annual operating burn rate
- Extreme leverage with debt-to-equity of 4.46x and negative interest coverage of -8.4x creates default risk
- Catastrophic unit economics: -$2,588 net margin means $250.6M loss on only $9.7M revenue, indicating no viable path to profitability at current business model
Key Metrics to Watch
- Monthly cash balance and burn rate trajectory relative to 4-month runway estimate
- Revenue growth sustenance and gross margin achievement once commercial scale reached
- Debt refinancing announcements or equity raise necessity and dilution impact
Precigen, Inc.. (PGEN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.09x current ratio provides a solid financial cushion.
PGEN Profit Margin, ROE & Profitability Analysis
PGEN vs Healthcare Sector: How Precigen, Inc.. Compares
How Precigen, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Precigen, Inc.. Stock Overvalued? PGEN Valuation Analysis 2026
Based on fundamental analysis, Precigen, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Precigen, Inc.. Balance Sheet: PGEN Debt, Cash & Liquidity
PGEN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Precigen, Inc..'s revenue has declined by 96% over the 5-year period, indicating business contraction. The most recent EPS of $-0.39 indicates the company is currently unprofitable.
PGEN Revenue Growth, EPS Growth & YoY Performance
PGEN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2023 | $1.8M | -$17.6M | $-0.08 |
| Q1 2023 | $1.9M | -$19.3M | $-0.10 |
| Q3 2022 | $3.3M | -$29.8M | $-0.04 |
| Q2 2022 | $2.9M | -$17.6M | $-0.09 |
| Q1 2022 | $24.5M | -$17.3M | $-0.09 |
| Q3 2021 | $21.6M | -$27.5M | $-0.15 |
| Q2 2021 | $30.4M | -$15.7M | $-0.10 |
| Q1 2021 | $24.5M | -$17.3M | $-0.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Precigen, Inc.. Dividends, Buybacks & Capital Allocation
PGEN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Precigen, Inc.. (CIK: 0001356090)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PGEN
What is the AI rating for PGEN?
Precigen, Inc.. (PGEN) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PGEN's key strengths?
Claude: Revenue growth of 146.7% YoY demonstrates market traction from near-zero baseline. Short-term liquidity ratios (3.09x current, 3.08x quick) provide immediate payment capacity.
What are the risks of investing in PGEN?
Claude: Critical cash runway of only 4 months at current -$87.8M annual operating burn rate. Extreme leverage with debt-to-equity of 4.46x and negative interest coverage of -8.4x creates default risk.
What is PGEN's revenue and growth?
Precigen, Inc.. reported revenue of $9.7M.
Does PGEN pay dividends?
Precigen, Inc.. does not currently pay dividends.
Where can I find PGEN SEC filings?
Official SEC filings for Precigen, Inc.. (CIK: 0001356090) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PGEN's EPS?
Precigen, Inc.. has a diluted EPS of $-1.37.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PGEN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Precigen, Inc.. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PGEN stock overvalued or undervalued?
Valuation metrics for PGEN: ROE of -1,198.6% (sector avg: 15%), net margin of -2,588.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PGEN stock in 2026?
Our dual AI analysis gives Precigen, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PGEN's free cash flow?
Precigen, Inc..'s operating cash flow is $-87.8M, with capital expenditures of $2.0M. FCF margin is -927.6%.
How does PGEN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,588.2% (avg: 12%), ROE -1,198.6% (avg: 15%), current ratio 3.09 (avg: 2).
Is Precigen, Inc.. carrying too much debt?
PGEN has a debt-to-equity ratio of 4.46x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 3.09 suggests adequate short-term liquidity.